univers coverag
calendar event
analyst confer call atop dermat still without ped
medacorp puls call gear aao surgeon perspect
robot total joint trend new product area estimate
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
regulatori fda adcom neurolog devic panel medic devic evalu
clinic data intracrani aneurysm treatment devic vaccin relat biolog
medic meet pittsburgh confer analyt chemistri appli
spectroscopi pittcon mobil world confer european congress radiolog
preview ph data obese/overweight diabet
probability-weight dcf analysi discount rate termin growth rate
bottom line zfgn share run advanc compani next data updat
design safer inhibitor beloranib differ tissu
distribut support usag overweight/obes diabet upcom studi expect
see efficaci mani relev clinic endpoint biomark bodi weight base
mechan action howev believ split among dose vs placebo
week studi like large/long enough produc statist signific benefit
primari endpoint typic requir mo evalu determin
clinic meaning drug effect therefor believ stock could pull back trend
toward signific seen primari endpoint safeti also great interest given past
experi beloranib larg non-orphan market zfgn current target
believ requir mani hundr thousand patient exposur adequ
derisk note take look preclin clinic data gener
date consid implic upcom data zfgn stock reiter mp
zfgn manag state recent global healthcar confer link would
like see dose respons
preclin data diabet obes mice show clear dose depend effect relev
clinic data healthi volunt show evid metabol benefit dose
respons case obese/diabet patient phase
project probabl make market gener peak gross sale
dcf translat ev/sal
bottom line deliv anoth solid qtr sale come slightli pre-announc
level y/i revenue growth beat vs consensu -- -and gm
expect management reiter least revenue growth gm outlook
continu confid abil sustain lead posit peripher
nerv repair also lead categori expand util larg significantli
under-penetrated core market opp ty uniqu barrier entri around flagship product avanc
nerv graft furthermor expect capit new market opportun breast reconstruct
neurot management estim market oppti surgic management pain
remain one top small-cap med-tech idea reiter op rate
dcf base pt increas vs lower assum out-year tax rate slightli higher out-
management reiter outlook call y/i growth gm
surgic pain manag could enorm oppti increment revenue growth still like
initi drive deeper account penetr pay
 beyond driver upsid model
recap bone program set enter clinic program
bottom line cmta releas earn disclos rare bone
diseas program remain track on-going pivot move trial palovaroten
fibrodysplasia ossifican progressiva fop continu plan compani
enter clinic program evalu palovaroten much larger indic multipl
osteochondroma mo addit open label extens studi updat part
expect fop program cmta end cash reiter op
pt
long-term focu fop cmta lead program fop track interim data readout
near-term focu fop catalyt data readout studi evalu palovaroten fop
guid
registr enabl phase mo-p studi plan initi
revenu ep conform ifr standard
solid result busi show rebound pt
bottom line express script post solid result core busi seem show
good rebound good gross margin growth appar solid retent expect
seemingli highli effect clinic program also like esrx push much
earn tax benefit adjust ep clearli balanc need
busi expect sharehold view op re-invest back
platform may long-term benefit busi howev would much
rather see focu sharehold return clinic program seem work well
safeguardrx product gain traction wbad jv effect improv
gener procur rate synergi like realiz specialti spend
complex product start flow wbad optimist outlook
evicor given improv fundament increas estim pt
esrx continu drive margin
sell season start
updat estim pt
revenu billion ep adjust non-cash non-recur item
in-lin ep target continu look achiev
sum-of-the-part weight average ev/ebitda multipl
bottom line major surpris quarter mid-point ep guidanc
in-lin previous state goal street expect busi remain strong
overal driven geograph diversif top-line growth expect north
america na continu see pressur us base gener busi expect sale
flat driven new product launch growth expect come europ eu
rest-of-world row market grow high singl digit highlight sever new product
could drive acknowledg uncertainli around time
view guidanc rang larg achiev continu see
potenti near term momentum stock upcom approv maintain market
perform rate look forward detail manag pipelin investor day
na sale expect flat new launch offset base eros
europ sale expect grow high singl digit driven continu growth base new launch
row growth driven portfolio expans across sever new geographi
make good progress biosimilar portfolio biosimilar herceptin
guidanc reason consid uncertainti head year
 methodolog dcf use wacc termin growth rate
bottom line manag sale guidanc exparel suggest growth high-
singl digit appear achiev given double-digit growth trend seen late
potenti addit traction op collabor uncertainti around
label expans nerv block current exparel use near term believ
stock could come pressur phase data competitor product
nerv block pdufa date april believ pacira potenti drive
meaning growth exparel longer term gain traction collabor
importantli potenti decoupl exparel reimburs wait sidelin
get better clariti updat model guidanc also
take opportun lower estim exparel reflect recent neg adcom
lower pt
exparel sale guidanc look achiev us manag view conserv
exparel could receiv j-code earli like start jan
effort underway gener addit data drive educ
pacira continu explor opportun beyond exparel
bottom line increas convict return behavior revenu growth
post ebitda ep beat strong volum cost control initi
revenu ebitda guidanc line midpoint behavior volum strong beat
consensu trend qoq yoy lo yoy articul steve filton
dinner confer feb volum demand off-set lo declin
view data point increas convict bh revenu growth return acut
volum also strong trend improv qoq yoy price weak like due lower
acuiti observ stay flu volum swb expens beat expect initi
ebitda revenu guidanc line consensu midpoint tax reform contribut
consensu ep guidanc expect color capit deploy call
well updat settlement process doj state feder agenc
ebitda ep beat revenu line
behavior remain track return revenu
acut volum strong trend improv qoq yoy price weak like due lower
acuiti observ stay flu volum
swb opex beat suppli miss
strong balanc sheet leverag ratio view floor debt ebitda compani
initi revenu ebitda guidanc line midpoint
remain activ purchas stock repo
manag host confer call eastern time thursday march dial-
number
pleas see link call held dinner manag feb link feb
present leerink global confer link
refus etrasimod base ozanimod rtf
bottom line although arena etrasimod similar mechan receptor
agon celgen celg op ozanimod news fda refus file rtf letter
latter necessarili read neg etrasimod long run
view admittedli ozanimod rtf like put greater emphasi scrutini etrasimod pk/
pd well safeti profil data moderate-to-sever ulcer coliti uc
announc quarter believ air like come broader balloon today
celg news although continu see signific upsid etrasimod highlight
recent data preview/scenario analysi link earli etrasimod data keep us optimist
greater select optim pk/pd therefor potenti superior safety/efficaci profil
could differenti agonist allow address mani lucr autoimmun
indic link reiter op
recap advisori committe pdufa june
multipl dcf analysi discount rate termin growth rate
bottom line yesterday close akao report net loss line
estim management focus upcom advisori committe launch
prepar plazomicin gram neg infect reiter confid chang
statu mp mcpherson facil remov overhang support potenti
approv pend inspect reiter op rate price target management continu
prepar advisori committe expect occur next two month continu
believ label key topic discuss view plazo data carbapenem-resist
enterobacteriacea studi support pathogen-specif indic within
bloodstream infect addit compani recent complet build-out commerci team
expect sale forc rep suffici commerci plazomicin us partner
thermo-fish op recent notifi akao accept review notif
therapeut drug manag assay updat model quarter incorpor
fda accept plazomicin nda file resolut mcpherson warn letter long
term tax rate adjust balanc recent equiti dilut total neutral
price target
 methodolog price-to-earnings ep
bottom line updat aet model ep beat in-lin revenu qualiti
weaker peer meaning yoy declin day claim payabl ep goe
post guid tax reform tailwind ep goe contempl
one-year hipf delay op aet commenc anti-trust hear sharehold vote
expect march expect anti-trust scrutini go expect stock
would go deal break close stock under-perform peer tax reform pt
contempl price-to-earnings ep current share price deal
valu per aet share includ cash share per aet share
revenu present million revenu exclud net realiz capit gain non-gaap adjust
ep quarter may sum total due round
recap phase strive data end
blend revenu multipl dcf analysi
bottom line tuesday market close cdtx announc result ep
slightli lower estim driven margin higher oper
expens compani reiter guidanc top-lin data phase strive studi
rezafungin iv candidemia invas candidiasi end preview
phase data deep dive link believ rezafungin offer credibl answer key
question predict efficaci profil anti-infect medicin ahead proof-of-concept data
quarter updat model maintain price reiter op
cdtx
sale
bottom line yesterday market close report sale y/i
ahead pre-announce revenu januari beat estim
street estim time pre-announce out-performance larg driven
commerci patient deliv strongest commerci growth intern grew
manag reiter recent issu revenu guidanc y/
mid-point vs estim street estim prior full earn
releas last night line question call post-cal suggest investor concern
guidanc total sale suggest below-street estim wed note
street mis-model sale given histor trend sinc
suggest sale total annual sale also believ manag annual
guidanc leav signific room upsid regard pipelin manag gave us
confid calibr expect launch manag contempl
sever factor reiter guidanc includ launch ramp medicar competit launch
price pressur inclin think manag exercis prudent conservat
reset street expect light fairli unpredict move part given on-going
competit pressur mp libr lower-than-consensu guidanc
expect stock trade today like stori see increasingli
favor risk/reward profil continu recommend buy weak particularli
investor month time horizon
revenu million
recap eye set pompe/fabri updat pt
bottom line cap galafold migalastat first yr commerci eu pave way
addit growth ww regulatori decis anticip japan us complement
updat compani drug candid pomp diseas regard
latter studi enrol pt observ studi like retrospect
stride prospect contextu natur histori compar data pt
current standard care soc regulatori updat could determin whether earli
file therefor earlier market entri possibl pomp updat model incorpor financi
result reiter op decreas pt previous increas expens
revenu mm ep
anoth rais momentum set continu pt
 methodolog ev/sal multipl sale
bottom line extend streak consecut rev/ep beat face
estim near high end guidanc compani maintain solid execut momentum
revenu y/i came ahead us/consensu translat strong
non-gaap ep beat vs us vs street project underscor compani
on-going posit leverag driven part mix shift toward direct-to-consum dtc busi
lower materi cost rais sale guidanc midpoint reflect beat
guid like continu reflect conservat management
revenu million ep
ceo chg portend better management account possibl precursor
bottom line morn ivti announc philip sawyer resign posit ceo
current board member scott flora serv interim presid chief execut
offic ivti search perman replac think ceo resign view
posit -- -a sign board recogn need increas account execut follow
stretch choppy/unpredict result view may potenti even signal compani
could will entertain possibl strateg option go forward outright sale
compani though clear mention press releas current depress
stock level believ valuat disconnect compani longer term growth profil
larg part b/c stress cash posit co like need rais money point
believ stock worth least use ev/sal multipl
end day ivti dd top-lin grower would reflect healthi upsid ivti
stock price ivti show-m stori could take sever qtr improv execut re-
instil investor confid level see risk-reward skew upsid especi
given view ivti portfolio could offer strateg valu larger medic devic compani
call point multipl call point across gen surgeri orthoped gyn plastic surgeri
outperform market cap price price target methodolog dcf
bottom line today prqr releas full year earn result link management plan
keep one foot cystic fibrosi cf space former lead program current
paus posit studi link expect initi assum secur
partnership prqr priorit program rare diseas pipelin despit prqr
refocus program discuss leerink global healthcar confer link remain
encourag rna base technolog look forward month safeti efficaci data
leber congenit amaurosi type interim data
dystroph epidermolysi bullosa/deb ahead addit catalyst prqr report
cash expect fund program anticip clinic data readout accord
press releas ep per share ye ep per share reiter op
ifr revenu million
recap green light fsg trial pipelin develop growth base
bottom line highlight earn call unquestion fda written approv
rtrx statist model correl chang proteinuria estim glomerular filtrat
rate egfr patient suffer focal segment glomerular sclerosi fsg allow
compani proceed trial evalu lead candid sparsentan
indic meanwhil management state develop three clinic program
remain track demonstr growth base busi illustr yoy
growth total revenu opinion think revenu base
becom much diversifi therebi reduc risk generic lead asset
thiola even asset may de-risk nda next gener
thiola formul file approv posit compani possibl higher
revenu multipl stock reiter op pt
revenu million
zejula sale miss guidanc consensu pt
 methodolog blend stand-alon dcf takeout analysi base
bottom line last night close tsro report earn zejula niraparib
parp inhibitor sale consensu estim respect
toward lower end compani previou guidanc tsro also issu guidanc
ww zejula sale previou estim consensu
base guidanc provid call made sever chang model
detail insid note result dcf valuat addit
recent decreas consensu sale estim lower p/s-base takeout analysi
result new blend price target previous regardless
year number continu see parp inhibitor market larg believ
zejula safeti side-effect issu manag dose select await data
topacio trial zejula mp keytruda pembrolizumab ovarian cancer
sgo march triple-neg breast cancer june next major catalyst
revenu est reflect convers prefer common share plu ipo share
quarter sum fy due secondari offer
high-growth end mkt still risk-reward upsid view
bottom line deliv rev pre-announc eps/ebitda beat
offici revenue guidanc in-lin though ebitda outlook consensu still
improv y/i margin believ compani remain track achiev
ebitda margin continu believ end-market remain healthi grow
well posit take share within drive hsd sell day
adj growth acceler potenti low-teen think wmgi share
rebound depress level conting upon steadili improv lower extrem revenue growth move
recent hire lower extrem rep hire come product curv new lower extrem
prod launch pick steam greater clariti improv b/ cash rais sort
like next month view reiter op pt goe vs due lower
cash/ev assumpt base sale
rev/ep continu oper ex-larg joint move disc op ep ex-amort item
wba-abc talk ez come ez go read-across mco
miss tough guid pt lower expect requir re-
 methodolog blend dcf analysi discount rate termin
growth revenu multipl valuat
rais pt quarter guidanc high end
 methodolog ev/ebitda adjust ebitda
recap strong quarter growth base biz/pt
mani self inflict wound excus ozanimod delay least
 methodolog averag method dcf price earn price sale
lower estim setup look favor
ev/ebitda multipl
result solid guidanc
sentiment neg sever shot goal provid longer term opp ty
dcf analysi discount rate termin growth rate
earn miss due higher sale guidanc reiter
continu like setup
cash flow use wacc termin growth rate
solid effort stabil acthar progress take time
 methodolog dcf use discount rate termin growth
cut bait vibativ anoth jaki surfac pt
 methodolog dcf use dr tgr
 methodolog ev/ebitda analysi sotp estim rang
recap execut drive test adopt conserv
solid rev/ep new product cycl stori pt
 methodolog dcf sotp impli ev/sal
luspatercept progress muscl program offer long term upsid pt
 methodolog npv analysi discount rate termin growth rate
recap deep pipelin provid shot goal phase start
analysi discount rate termin growth rate
hcit distribut preview posit coordin vbc cautiou
 preview tax reform guidanc imp catalyst aet
medic suppli devic individu co preview cardio large-cap diversifi
march addit phase apollo data patisiran ttr
addit data apollo trial present intern symposium
breadth label remain key subject invest debat
management express confid get broad label note mani specialist
view hereditari ttr amyloidosi hattr singl condit vs two separ
polyneuropathi cardiomyopathi condit
fda action date pdufa august
approv expect launch patisiran us
expect submit new drug applic nda ali march prioriti
previous guid remain track expect advisori committe meet
adcom amikacin liposom inhal suspens ali refractori nontubercul
mycobacteri lung infect ntm caus mycobacterium avium complex
stock come investor question efficaci long-term durabl
approv believ fda panelist could view posit
extens studi data refractori ntm patient favor
believ discuss point may even consid possibl ali front-lin
therapi ahead guidelin base therapi fda-approv
addit ali data american thorac societi meet may
cdtx rezafungin iv phase ii data candidemia system candida
phase ii strive data rezafungin iv expect
cdtx share sold significantli earlier topic program
vulvovagin candidiasi discontinu think perceiv read-through
error continu ascrib odd approv underlin robust pharmacokinet
preclin safeti histor echinocandin data
project probability-weight rezafungin sale
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
hyperhidrosi excess sweat pdufa probability-of-
follow recent success complet futil analysi ph
studi asah patient pivot event edg share set in/around
compani conduct interim analysi see binari event
upsid skew risk/reward
compar vs standard care oral nimodipin asah
succeed interim analysi need better oral nimodipin
base case assum odd success
project probability-weight sale
ionis-httrx phase ib data earli albeit under-follow clinic event
think could offer import proof-of-principl antisens strategi huntington diseas
signific unmet medic need hd repres massiv potenti market
opportun novel disease-modifi strategi
upcom ionis-httrx result import potenti roch
also see meaning read-through op whose antisens hd program also
phase ib month behind
project ionis-httrx probability-adjust sale eu
receiv mid-teen royalti
top-lin result expect earli studi test rationally-
design formul commens bacteria resolv dysbiosi colon
manag believ dysbiosi primari cdi less sever effect restor
use lower number bacteri strain compar recurr cdi target
predict probabl success peak risk-adjust us gross
sale estim
believ posit result could enhanc appreci mcrb spore-bas approach
restor gut microbiom provid insight util synthet microbiom
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
also optimist odds-of-success elagolix uterin fibroid -- consist
consensu view program
partner elagolix mp fund clinical/commerci
develop agre pay royalti sale
mileston
elagolix daili oral gnrh gonadatropin-releas hormon antagonist two
posit ph data set endometriosi uf larger market
forecast gross peak revenu elagolix endometriosi
probabl success po uf po
april pdufa rubraca ovarian cancer
rubraca saw slow launch result competit posit platinum-
rubraca first parp inhibitor us approv line set brca patient
howev product tsro op zejula azn mp lynparza surpass
us approv earlier broader line mainten set pressur rubraca
demand line
us approv rubraca broad line mainten indic pdufa date april
import growth driver product competit profil accord
physician survey
continu believ parp inhibitor address potenti larg market
opportun across sever tumor type beyond ovarian cancer among prostat
cancer repres particularli attract opportun pivot trial
well underway interim data expect
burosumab recent receiv posit eu chmp decis x-link hypophosphataemia
xlh believ encourag
burosumab adult xlh pt demonstr continu stabil serum phosphoru
level improv secondari endpoint stiff physic function pain
addit possibl disease-modifi characterist improv bone health
posit chmp decis provid credenc favor top-lin ph data initi
pdufa date fda advisori committe meet expect
storm phase ii studi selinexor penta-refractori multipl myeloma mm
full interim storm result selinexor low-dos dexamethason dex first
patient highlight drug single-ag activ difficult-to-treat patient --
management believ bode well approv probabl drug
prior data indic solid activ orr overal respons rate across
variou subgroup quad penta-refractori pt
top-lin storm ph ii data expand trial expect april
bold ph i/ii xlmtm crigler-najjar syndrom data
audent expect announc updat phase i/ii aspiro data x-link
myotubular myopathy/xlmtm well preliminari phase i/ii valen data crigler-
najjar syndrom
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
sourc leerink research compani inform factset price prior day
fda adcom neurolog devic panel medic devic evalu clinic
data intracrani aneurysm treatment devic
fda adcom vaccin relat biolog product
fda adcom brief document oncolog drug sbla blincyto
fda adcom brief document gastrointestin drug panel snda
fda adcom oncolog drug sbla blincyto
fda adcom gastrointestin drug panel snda xeljanz ulcer
fda adcom joint meet blood product microbiolog devic
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
fda adcom endocrinolog metabol drug
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa revefanacin lama copd
pittsburgh confer analyt chemistri appli spectroscopi
european congress radiolog ecr
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
american colleg cardiolog cardiovascular
societi inherit metabol disord
societi toxicolog
intern confer alzheim parkinson diseas
 canadian academi patholog
intern confer ureagenesi defect
societi surgic oncolog
american academi osteopathi
societi gynecolog oncolog
intern societi amyloidosi
american colleg medic genet genom
intern societi heart lung transplant
societi american gastrointestin endoscop surgeon
american societi laser medicin surgeri
european associ studi liver
american societi cataract refract surgeri
american associ cancer research
molecular target tripl meet aacr-nci-eortc
hcit distribut preview posit coordin vbc cautiou
 preview tax reform guidanc imp catalyst aet
medic suppli devic individu co preview cardio large-cap diversifi
 panel offer insight evolv dynam psych
 test fda flexibl pt higher
 look migrain relief closer look oral cgrp outperform
 management dinner recap comb everi detail phase ii
 research event shine light expand earli pipelin
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
aciu -- flash aciu takeaway leerink global healthcar confer
aciu kol lunch support target tau ad interim look advanc
aciu recap pipelin w/ new antibodi select cren
aciu -- flash aciu receiv chf roch phase initi anti-
-- flash aducanumab phase trial expand variabl endpt requir
-- flash takeaway leerink global healthcar confer
 growth margin management stabil still lack pipelin catalyst
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 roll new ttr model updat spinraza pipelin pt market
 leerink confer highlight dinner manag market
 apec studi discontinu remov verubecestat model pt
 state larg cap biotech sfo steadi goe
chang
 first apprais tax offer small benefit
 vertex alexion top pick
 ttr seri part handicap on-going tafamidi trial fac
 growth deal capac target market
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
 leerink confer highlight dinner manag market
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc highlight nvo management roundtabl discuss boston market
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biotechnology/aan recap sma steal show migrain epilepsi pd psych
 futur major invest theme backdrop
 neurosci panel takeaway leerink global
gwph lower pt better data setup still solid
 build solid foundat xlh data could posit ahead
 own dont part wake
-- flash kol call po risk/benefit support major role orphan
 investor sleep path ip protect pt
management dinner offer perspect pdp launch/strategi
 management dinner offer perspect pdp launch/strategi potenti
-- flash dementia psychosi btd po surpris basket high risk/
 remov toz model safeti setback all-in pt
re-fil inbrija nda parkinson diseas episod believ issu
 kol dinner offer insight emerg drug psych
 recap sma steal show migrain epilepsi pd psych
 upgrad op overhang remov shot base fda/cn
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut outlin possibl drug price polici
draconian fear
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
novob dc disappoint oral sema currenc price fear bake
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
 respit price yet friendli hill fda
could longer term
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 news patent decis one remind method use
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
 increas pt takeda collabor stock weak offer oppti
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 gwph major takeaway weekend annual
epilepsi meet
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 initi
 analyst event best idea
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
medic suppli devic survey direct posit
mute hope new indications/improv execut
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
biopharma atop derm still without ped leerink dupi derm
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng
outlook gsk
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit
azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup
 physician survey support nerlynx opp ty breast cancer pt
medic devic survey direct posit mute
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
